Fulcrum Therapeutics
FULC
101 hedge funds and large institutions have $412M invested in Fulcrum Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 11 closing their positions.
469% more call options, than puts
Call options by funds: $4.61M | Put options by funds: $811K
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
65% more capital invested
Capital invested by funds: $250M → $412M (+$162M)
25% more funds holding
Funds holding: 81 → 101 (+20)
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
7.59% more ownership
Funds ownership: 91.22% → 98.81% (+7.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.32M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.65M |
| 3 |
Goldman Sachs
New York
|
+$2.72M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$2.11M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.99M |
| 2 |
CAC
Cowen and Company
New York
|
-$3.7M |
| 3 |
Millennium Management
New York
|
-$2.52M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.41M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.31M |
FULC Hedge Fund Activity: Q4 2023 in Review
101 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2023, worth a combined $412M — up 65% from $250M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new FULC positions and 11 closed out — a net gain of 20 holders — while 24 added to existing stakes and 21 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $5.32M. The largest seller was Adage Capital Partners, cutting an estimated $3.99M.
- 101 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2023, up from 81 in Q3 2023.
- Funds reported $412M of Fulcrum Therapeutics stock for Q4 2023, up 65% quarter-over-quarter.
- 31 funds opened new Fulcrum Therapeutics positions in Q4 2023 and 11 closed out, a net change of +20 holders.
- The largest Fulcrum Therapeutics buyer in Q4 2023 was Logos Global Management, an estimated $5.32M added.
- The largest Fulcrum Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $3.99M sold.
Based on aggregated 13F filings for Q4 2023.